A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target

The identification of drug targets is highly challenging, particularly for diseases of the brain. To address this problem, we developed and experimentally validated a general computational framework for drug target discovery that combines gene regulatory information with causal reasoning (“Causal Reasoning Analytical Framework for Target discovery”—CRAFT). Using a systems genetics approach and starting from gene expression data from the target tissue, CRAFT provides a predictive framework for identifying cell membrane receptors with a direction-specified influence over disease-related gene expression profiles. As proof of concept, we applied CRAFT to epilepsy and predicted the tyrosine kinase receptor Csf1R as a potential therapeutic target. The predicted effect of Csf1R blockade in attenuating epilepsy seizures was validated in three pre-clinical models of epilepsy. These results highlight CRAFT as a systems-level framework for target discovery and suggest Csf1R blockade as a novel therapeutic strategy in epilepsy. CRAFT is applicable to disease settings other than epilepsy.The identification of new drug targets is highly challenging, particularly for diseases of the brain. This study describes a general computational gene regulatory framework called CRAFT for drug target discovery, and the authors use CRAFT to identify the microglial membrane receptor Csf1R as a potential therapeutic target for epilepsy.

[1]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[2]  Slave Petrovski,et al.  Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus , 2015, Nature Communications.

[3]  J. H. Ward.  Hierarchical Grouping to Optimize an Objective Function , 1963 .

[4]  S. Horvath,et al.  Global changes in patterning, splicing and primate specific lncRNAs in autism brain , 2016, bioRxiv.

[5]  Harry W. Clifford,et al.  Comparison of Clustering Methods for Investigation of Genome-Wide Methylation Array Data , 2011, Front. Gene..

[6]  R. Racine,et al.  Modification of seizure activity by electrical stimulation. 3. Mechanisms. , 1972, Electroencephalography and clinical neurophysiology.

[7]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[8]  E. Schadt.  Molecular networks as sensors and drivers of common human diseases , 2009, Nature.

[9]  Christina Kendziorski,et al.  Statistical methods for gene set co-expression analysis , 2009, Bioinform..

[10]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[11]  Y. Berdichevsky,et al.  Interictal Spikes Precede Ictal Discharges in an Organotypic Hippocampal Slice Culture Model of Epileptogenesis , 2010, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[12]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[13]  Michael R. Johnson,et al.  Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery , 2016, Genome Biology.

[14]  A. Vezzani.  Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis? , 2015, Expert opinion on drug safety.

[15]  Wolfgang Löscher,et al.  Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs , 2011, Seizure.

[16]  A. Depaulis,et al.  Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy , 2016, CNS neuroscience & therapeutics.

[17]  W. Löscher,et al.  Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice , 2007, Experimental Neurology.

[18]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[19]  Giovanni Coppola,et al.  A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program , 2016, Neuron.

[20]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[21]  Dieter Schmidt,et al.  New avenues for anti-epileptic drug discovery and development , 2013, Nature Reviews Drug Discovery.

[22]  A. Vezzani,et al.  Interleukin‐1 type 1 receptor/Toll‐like receptor signalling in epilepsy: the importance of IL‐1beta and high‐mobility group box 1 , 2011, Journal of internal medicine.

[23]  Michael R. Johnson,et al.  Intrinsic Severity as a Determinant of Antiepileptic Drug Refractoriness , 2008, Epilepsy currents.

[24]  Doug Speed,et al.  Systems genetics identifies a convergent gene network for cognition and neurodevelopmental disease , 2015, Nature Neuroscience.

[25]  Luis de la Torre Ubieta,et al.  Genome-wide changes in lncRNA, alternative splicing, and cortical patterning in autism , 2016 .

[26]  Jaap Heringa,et al.  Accurate confidence aware clustering of array CGH tumor profiles , 2010, Bioinform..

[27]  A. Vezzani,et al.  Intrinsic Inflammation Is a Potential Anti-Epileptogenic Target in the Organotypic Hippocampal Slice Model , 2018, Neurotherapeutics.

[28]  M. Wong.  Epilepsy in a Dish: An in Vitro Model of Epileptogenesis , 2011, Epilepsy currents.

[29]  Julio Saez-Rodriguez,et al.  A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions , 2015, PloS one.

[30]  A. Lusis,et al.  Systems genetics approaches to understand complex traits , 2013, Nature Reviews Genetics.

[31]  R. Racine,et al.  Modification of seizure activity by electrical stimulation. II. Motor seizure. , 1972, Electroencephalography and clinical neurophysiology.

[32]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[33]  H. Gevensleben,et al.  Transcription factors link mouse WAP‐T mammary tumors with human breast cancer , 2013, International journal of cancer.

[34]  Daniel H. Geschwind,et al.  Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders , 2015, Nature Reviews Genetics.

[35]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[36]  Michael R. Johnson,et al.  Describing the genetic architecture of epilepsy through heritability analysis , 2014, Brain : a journal of neurology.

[37]  K. Green,et al.  Characterizing Newly Repopulated Microglia in the Adult Mouse: Impacts on Animal Behavior, Cell Morphology, and Neuroinflammation , 2015, PloS one.

[38]  S. Spencer,et al.  Seizure Clustering during Epilepsy Monitoring , 2002, Epilepsia.

[39]  Etienne Hanon,et al.  Proepileptic phenotype of SV2A‐deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam , 2009, Epilepsia.

[40]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[41]  Martin Vingron,et al.  A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk , 2010, Nature.

[42]  R. Dingledine,et al.  The role of inflammation in epileptogenesis , 2013, Neuropharmacology.

[43]  Robert Tibshirani,et al.  Estimating the number of clusters in a data set via the gap statistic , 2000 .

[44]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[45]  Andrew White,et al.  EEG spike activity precedes epilepsy after kainate‐induced status epilepticus , 2010, Epilepsia.

[46]  D. Tousoulis,et al.  The Role of Inflammation , 2018 .

[47]  Dudley J Pennell,et al.  Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass , 2008, Nature Genetics.

[48]  G. Mortier,et al.  qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.

[49]  Jung Eun Shim,et al.  TRRUST: a reference database of human transcriptional regulatory interactions , 2015, Scientific Reports.

[50]  Laleh Soltan Ghoraie,et al.  A review of connectivity map and computational approaches in pharmacogenomics , 2017, Briefings Bioinform..

[51]  S. Linnarsson,et al.  Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq , 2015, Science.

[52]  T. Caliński,et al.  A dendrite method for cluster analysis , 1974 .

[53]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[54]  M. Mazzuferi,et al.  Rapid epileptogenesis in the mouse pilocarpine model: Video-EEG, pharmacokinetic and histopathological characterization , 2012, Experimental Neurology.

[55]  Leif E. Peterson.  CLUSFAVOR 5.0: hierarchical cluster and principal-component analysis of microarray-based transcriptional profiles , 2002, Genome Biology.

[56]  W. Löscher,et al.  Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice , 2015, Neuropharmacology.

[57]  Mariano J. Alvarez,et al.  Identification of Causal Genetic Drivers of Human Disease through Systems-Level Analysis of Regulatory Networks , 2014, Cell.

[58]  Brian L. West,et al.  Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain , 2014, Neuron.

[59]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[60]  B. Danis,et al.  Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy , 2013, Annals of neurology.

[61]  D. Budd,et al.  Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. , 2011, Blood.

[62]  G. Habets,et al.  The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML, , 2011 .

[63]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[64]  Yutaka Suzuki,et al.  Conditional rod photoreceptor ablation reveals Sall1 as a microglial marker and regulator of microglial morphology in the retina , 2016, Glia.

[65]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[66]  T. Decker,et al.  A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. , 1988, Journal of immunological methods.

[67]  R. Myers,et al.  Circadian patterns of gene expression in the human brain and disruption in major depressive disorder , 2013, Proceedings of the National Academy of Sciences.

[68]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[69]  Josemir W Sander,et al.  Life expectancy in people with newly diagnosed epilepsy. , 2004, Brain : a journal of neurology.

[70]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.